CXCL1 and neoplasm: TPL2 signaling can further interfere with lymphocyte-mediated anti-tumor immunity by enhancing the infiltration of immunosuppressive cells such as Treg cells and MDSCs through the induction of CCL22, CXCL1 and CXCL2 94-96.